227 related articles for article (PubMed ID: 32610643)
1. Antimycobacterial Effects of Everolimus in a Human Granuloma Model.
Ashley D; Hernandez J; Cao R; To K; Yegiazaryan A; Abrahem R; Nguyen T; Owens J; Lambros M; Subbian S; Venketaraman V
J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32610643
[No Abstract] [Full Text] [Related]
2. The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses against
To K; Cao R; Yegiazaryan A; Owens J; Sasaninia K; Vaughn C; Singh M; Truong E; Sathananthan A; Venketaraman V
Biomol Concepts; 2021 May; 12(1):16-26. PubMed ID: 33966361
[TBL] [Abstract][Full Text] [Related]
3. Cyclic Peptide [R
Hernandez J; Ashley D; Cao R; Abrahem R; Nguyen T; To K; Yegiazaryan A; Akinwale David A; Kumar Tiwari R; Venketaraman V
Front Immunol; 2020; 11():1677. PubMed ID: 32973740
[TBL] [Abstract][Full Text] [Related]
4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the mTOR Pathway for Tuberculosis Treatment.
Singh P; Subbian S
Front Microbiol; 2018; 9():70. PubMed ID: 29441052
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in
Cerni S; Shafer D; To K; Venketaraman V
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30754665
[TBL] [Abstract][Full Text] [Related]
9. Effects of Everolimus in Modulating the Host Immune Responses against
Raien A; Davis S; Zhang M; Zitser D; Lin M; Pitcher G; Bhalodia K; Subbian S; Venketaraman V
Cells; 2023 Nov; 12(22):. PubMed ID: 37998388
[TBL] [Abstract][Full Text] [Related]
10. FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.
Wang J; Sha J; Strong E; Chopra AK; Lee S
Microbiol Spectr; 2022 Oct; 10(5):e0250922. PubMed ID: 36129262
[TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
Tasneen R; Mortensen DS; Converse PJ; Urbanowski ME; Upton A; Fotouhi N; Nuermberger E; Hawryluk N
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0025321. PubMed ID: 33903099
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy.
Ouyang Q; Zhang K; Lin D; Feng CG; Cai Y; Chen X
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269154
[TBL] [Abstract][Full Text] [Related]
13. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
14. Host-Directed Therapeutic Strategies for Tuberculosis.
Kolloli A; Subbian S
Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the Efficacy of the Bacille Calmette-Guérin Vaccination in Conjunction with First Line Antibiotics and Liposomal Glutathione.
Abrahem R; Cao R; Robinson B; Munjal S; Cho T; To K; Ashley D; Hernandez J; Nguyen T; Teskey G; Venketaraman V
J Clin Med; 2019 Sep; 8(10):. PubMed ID: 31569759
[No Abstract] [Full Text] [Related]
16. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
17. Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology.
Chandra P; Rajmani RS; Verma G; Bhavesh NS; Kumar D
mSphere; 2016; 1(2):. PubMed ID: 27303736
[TBL] [Abstract][Full Text] [Related]
18. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
